Cardiovascular Diabetology
Papers 2133
1 page of 214 pages (2,133 results)
#1Fang-Ju Lin (NTU: National Taiwan University)H-Index: 12
#2Chi-Chuan Wang (NTU: National Taiwan University)H-Index: 16
Last. Huang Tz Ou (NCKU: National Cheng Kung University)H-Index: 14
view all 6 authors...
BACKGROUND To assess the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) for type 2 diabetes on kidney outcomes stratified by patient baseline estimated glomerular filtration rate (eGFR) levels (i.e., eGFR ≤ 60, 60 90 mL/min/1.73 m2). METHODS Patients from three large healthcare delivery systems in Taiwan who had initiated SGLT-2is or other glucose-lowering drugs (oGLDs) between May 2016 and December 2017 were included. Main outcomes were the times to 30%, 40%, and 50% eGFR reduct...
#1Alexander Zabala (KI: Karolinska Institutet)H-Index: 1
#2Vladimer Darsalia (KI: Karolinska Institutet)H-Index: 19
Last. Thomas Nyström (KI: Karolinska Institutet)H-Index: 30
view all 9 authors...
BACKGROUND AND AIMS Insulin resistance contributes to the development of type 2 diabetes (T2D) and is also a cardiovascular risk factor. The aim of this study was to investigate the potential association between insulin resistance measured by estimated glucose disposal rate (eGDR) and risk of stroke and mortality thereof in people with T2D. MATERIALS AND METHODS Nationwide population based observational cohort study that included all T2D patients from the Swedish national diabetes registry betwe...
#1Bradley Sarak (U of T: University of Toronto)H-Index: 2
#2Subodh Verma (U of T: University of Toronto)H-Index: 95
Last. Vineeta AhoojaH-Index: 1
view all 15 authors...
Sodium-glucose cotransporter 2 (SGLT2) inhibition reduces cardiovascular events in type 2 diabetes (T2DM) and is associated with a reduction in left ventricular (LV) mass index. However, the impact on right ventricular (RV) remodeling is unknown. Accordingly, the objective of this study was to assess the impact of SGLT2 inhibition on RV parameters and function in T2DM and coronary artery disease (CAD). In EMPA-HEART CardioLink-6, 97 patients with T2DM and CAD were randomly assigned to empagliflo...
#1Zhaoyang Hu (Sichuan University)H-Index: 12
#2Feng Ju (Sichuan University)
Last. Geoffrey W. Abbott (UCI: University of California, Irvine)H-Index: 33
view all 4 authors...
BACKGROUND Empagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used to lower blood sugar in adults with type 2 diabetes. Empagliflozin also exerts cardioprotective effects independent from glucose control, but its benefits on arrhythmogenesis and sudden cardiac death are not known. The purpose of this study was to examine the effect of empagliflozin on myocardial ischemia/reperfusion-provoked cardiac arrhythmia and sudden cardiac death in vivo. METHODS Male Sprague Dawl...
#1Leszek Czupryniak (Medical University of Warsaw)H-Index: 20
#2Dror Dicker (TAU: Tel Aviv University)H-Index: 14
Last. Guntram SchernthanerH-Index: 67
view all 5 authors...
Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a return to normal care after resolution of Covid-19 symptoms. Due to the sudden onset of the pandemic, physicians have by necessity made such important clinical decisions in the absence of robust evidence or consistent guidelines. The risk to patients is compounded by the prevalence of cardiovascular d...
#1Andrea Natali (UniPi: University of Pisa)H-Index: 61
#2Lorenzo Nesti (UniPi: University of Pisa)H-Index: 7
Last. Ele FerranniniH-Index: 110
view all 4 authors...
The impressive results of recent clinical trials with glucagon-like peptide-1 receptor agonists (GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular protection prompted a huge interest in these agents for heart failure (HF) prevention and treatment. While both classes show positive effects on composite cardiovascular endpoints (i.e. 3P MACE), their actions on the cardiac function and structure, as well as on volume regulation, and their impact on HF-related ...
#1Matti A. Vuori (TYKS: Turku University Hospital)H-Index: 1
#2Jaakko Reinikainen (National Institute for Health and Welfare)H-Index: 5
Last. Allan Linneberg (UCPH: University of Copenhagen)H-Index: 91
view all 16 authors...
BACKGROUND The risk of heart failure among diabetic individuals is high, even under tight glycemic control. The correlates and mediators of heart failure risk in individuals with diabetes need more elucidation in large population-based cohorts with long follow-up times and a wide panel of biologically relevant biomarkers. METHODS In a population-based sample of 3834 diabetic and 90,177 non-diabetic individuals, proportional hazards models and mediation analysis were used to assess the relation o...
#1Jiyun Park (SMC: Samsung Medical Center)
#2Gyuri Kim (SMC: Samsung Medical Center)H-Index: 15
Last. Jae Hyeon Kim (SMC: Samsung Medical Center)H-Index: 24
view all 8 authors...
BACKGROUND Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/or fibrosis are associated with the development of incident heart failure (iHF), hospitalized HF (hHF), mortality, and CV death in both the general population and HF patients. METHODS We analyzed 778,739 individuals without HF and 7445 patients with pre-existing HF aged 40 to 80 ...
#1Manige Konig (Eli Lilly and Company)H-Index: 4
#2Matthew C. Riddle (OHSU: Oregon Health & Science University)H-Index: 66
Last. Hertzel C. Gerstein (McMaster University)H-Index: 118
view all 9 authors...
Background null The REWIND trial demonstrated cardiovascular (CV) benefits to patients with type 2 diabetes and multiple CV risk factors or established CV disease. This exploratory analysis evaluated the degree to which the effect of dulaglutide on CV risk factors could statistically account for its effects on major adverse cardiovascular events (MACE) in the REWIND trial. null Methods null Potential mediators of established CV risk factors that were significantly reduced by dulaglutide were ass...
#1Claudia R.L. Cardoso (UFRJ: Federal University of Rio de Janeiro)H-Index: 28
#2Cristiane A. Villela-Nogueira (UFRJ: Federal University of Rio de Janeiro)H-Index: 16
Last. Gil F. Salles (UFRJ: Federal University of Rio de Janeiro)H-Index: 33
view all 4 authors...
BACKGROUND Liver stiffness measurement (LSM, which reflects fibrosis) and controlled attenuation parameter (CAP, which reflects steatosis), two parameters derived from hepatic transient elastography (TE), have scarcely been evaluated as predictors of cardiovascular complications and mortality in individuals with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). METHODS Four hundred type 2 diabetic patients with NAFLD had TE examination (by Fibroscan®) performed at baseline. Multivari...
Top fields of study
Internal medicine
Type 2 diabetes
Diabetes mellitus